Cited by 31Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease

Open access
Sutphen, Courtney L., Fagan, Anne M., Holtzman, David M.·2014·Biological Psychiatry

Abstract

Alzheimer's disease (AD) is a growing health crisis around the world. Although significant progress has been made in our understanding of AD pathogenesis, there is currently no effective treatment to delay onset or prevent the disease. The focus has now shifted to the identification and treatment of AD in the early clinical stages as well as before cognitive symptoms emerge-during the long preclinical stage. It is possible that diagnosis of individuals with AD will be more accurate when clinical symptoms and signs are combined with biomarkers, which can improve both the diagnostic and prognostic accuracy of AD and its differentiation from the other neurodegenerative diseases. This review discusses fluid and imaging biomarkers that have shown promise in such areas, as well as some of the current challenges that face the field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2013.07.031

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Donepezil, rivastigmine, galantamine, memantine, and namzaric can temporarily alleviate or stabilize symptoms but cannot stop long-term progression and are associated with various side effects.

    “Medications such as donepezil (4),41–43 rivastigmine (5),44,45 galantamine (6),46–48 memantine (7),49,50 and namzaric (8)51,52 have been employed in clinical settings. While these drugs can temporarily alleviate or stabilize symptoms, they are unable to stop the long-term progression of the disease and are associated with various side effects.”

    From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [33]

    The Introduction (page not specified) says current Alzheimer’s therapies can provide modest, temporary improvement or stabilization in some patients but do not target the underlying pathology. It does not name the five drugs or document side effects for them; the adverse effect it mentions concerns a different, experimental drug. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Holtzman, David M.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2014-04
Volume
75
Issue
7
Pages
520-526
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2030596620
Cited by
31
References
103
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 5 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 4
FWCI
0.45
Type
journal article
Language
en
Open access
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Public Health Service (P01-26276)
  • National Institute on Aging (P 50 AG05681, P50AG005681, P01 AG0 3991, P01AG003991, P01AG026276)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, fluid biomarkers, imaging biomarkers, preclinical Alzheimer's disease, early diagnosis, diagnostic accuracy, prognostic accuracy
MeSH terms
Alzheimer Disease, Humans, Magnetic Resonance Imaging, Biomarkers, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review